- Trial phase
- Preclinical (Development Candidate Selected)
- Time to market
- SEP-204 is in preclinical development with a Phase 1 trial planned to begin in Q1 2027. Assuming successful clinical development, potential approval would likely be several years away, likely in the 2030s if at all.
- Why 3/10
- SEP-204 is a preclinical program that was just selected as a development candidate on November 4, 2026. The next hard catalyst is the planned Phase 1 trial initiation in Q1 2027, roughly 4-5 months out. This is a milestone event, not a binary data readout, and SEP-204 is not Septerna's lead asset (SEP-631 is further along). The impact score is low because the drug is preclinical and the next catalyst is a Phase 1 start rather than a pivotal readout or regulatory decision.
The next catalyst for SEP-204 is the planned Phase 1 trial initiation in healthy volunteers in Q1 2027, roughly 4-5 months away. A successful start would validate the transition from preclinical to clinical-stage for this program, but the stock's bigger near-term driver is likely the Q3 2026 earnings report scheduled for November 25, 2026, and any updates on the more advanced SEP-631 (MRGPRX2 NAM) program.
Price Chart
Executive Summary
SEP-204 is an oral small molecule TSHR negative allosteric modulator (NAM) being developed by Septerna (NASDAQ: SEPN) for Graves' disease and thyroid eye disease (TED). On November 4, 2026, the company selected SEP-204 as a development candidate and presented preclinical data at the American Thyroid Association meeting showing potent TSHR inhibition, normalization of thyroid hormone levels, and reduced eye proptosis in animal models. The drug is still preclinical; a Phase 1 trial in healthy volunteers is planned for Q1 2027. Septerna has a strong cash position of $516.5 million (runway into 2029) and a broader pipeline led by SEP-631 (MRGPRX2 NAM) in Phase 2b-ready status. SEP-204 faces competition from Crinetics' CRN12755 (preclinical TSHR antagonist) and Lilly-acquired Merida Biosciences' MER-511 (Phase 1, different mechanism).
How It Works
SEP-204 is an oral pill that blocks the thyroid-stimulating hormone receptor (TSHR), a protein on cells in the thyroid gland and behind the eyes. In Graves' disease, the body's immune system produces antibodies that mistakenly activate this receptor, causing the thyroid to overproduce hormones (hyperthyroidism) and leading to eye bulging in thyroid eye disease. SEP-204 acts as a 'negative allosteric modulator,' meaning it binds to the receptor and dampens its overactivation without completely shutting it off, potentially treating both the thyroid and eye manifestations of the disease.
Trial Status
SEP-204 was selected as a development candidate on November 4, 2026, following preclinical studies that demonstrated potent and selective TSHR inhibition across biochemical, thyroid, and ocular endpoints. The drug was generally well tolerated in 28-day GLP toxicology studies in rats and dogs. A Phase 1 clinical trial in healthy volunteers is planned to initiate in the first quarter of 2027.
The Two-Sided Case
Upcoming Catalysts
- Phase 1 clinical trial initiation in healthy volunteers expected Q1 2027
- Q3 2026 earnings report scheduled for November 25, 2026 (broader company catalyst)
- Any updates on SEP-631 (MRGPRX2 NAM) Phase 2b development plans
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Septerna, Inc. Press Release SEPN ·Originating report